Cargando…
Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients
BACKGROUND AND PURPOSE: There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to d...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477135/ https://www.ncbi.nlm.nih.gov/pubmed/34611554 http://dx.doi.org/10.1016/j.ensci.2021.100369 |
_version_ | 1784575781472567296 |
---|---|
author | Ogura, Hiromu Hatip-Al-Khatib, Izzettin Suenaga, Midori Hatip, Funda Bolukbasi Mishima, Takayasu Fujioka, Shinsuke Ouma, Shinji Matsunaga, Yoichi Tsuboi, Yoshio |
author_facet | Ogura, Hiromu Hatip-Al-Khatib, Izzettin Suenaga, Midori Hatip, Funda Bolukbasi Mishima, Takayasu Fujioka, Shinsuke Ouma, Shinji Matsunaga, Yoichi Tsuboi, Yoshio |
author_sort | Ogura, Hiromu |
collection | PubMed |
description | BACKGROUND AND PURPOSE: There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to differentiate between healthy subjects (HS), multiple system atrophy (MSA) and Parkinson's disease (PD) patients of both genders. METHODS: A total of 107 subjects were included in this study, divided into three groups: 1- HS (n = 61), 2- MSA patients (n = 19), and 3- PD patients (n = 27). The patients were assessed using UMSARS II, UPDRS III, H&Y, MMSE and MoCA rating scales. The levels of 25(OH)D and 1,25(OH) 2 D in serum were determined using the radioimmunoassay technique. RESULTS: The levels of 25(OH)D and 1,25(OH) 2 D in HS were 26.85 +/− 7.62 ng/mL and 53.63 +/− 13.66 pg/mL respectively. 25(OH)D levels were lower in both MSA and PD by 61% and 50%, respectively (P = 0.0001 vs. HS). 1,25(OH) 2 D levels were lower in MSA by 29%(P = 0.001 vs HS). There was a correlation between 25(OH)D and 1,25(OH) 2 D in MSA and PD, but not in HS. 1,25(OH) 2 D regressed with MMSE (β = 0.476, P = 0.04, R 2 = 0.226) in MSA, and with UPDRS III (β = −0.432, P = 0.024, R 2 = 0.187) and MoCA (β = 0.582, P = 0.005,R 2 = 0.279) in PD. 25(OH)D displayed considerable differentiative strength between HS and MSA (Wald = 17.123, OR = 0.586, P = 0.0001; AUC = 0.982, sensitivity and Youden index = 0.882, P = 0.0001) and PD (Wald = 18.552, OR = 0.700, P = 0.0001; AUC = 0.943, sensitivity = 0.889, YI = 0.791, P = 0.0001). 1,25(OH) 2 D distinguished MSA from PD (Wald 16.178, OR = 1.117, P = 0.0001; AUC = 0.868, sensitivity = 0.926, Youden index =0.632, P = 0.0001). H&Y exhibited the highest sensitivity, AUC, and significant distinguishing power between MSA and PD. CONCLUSIONS: Serum 25(OH)D and 1,25(OH) 2 D could be useful biomarkers for MSA and PD. 25(OH)D and H&Y provided the highest sensitivity and group classification characteristics. |
format | Online Article Text |
id | pubmed-8477135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-84771352021-10-04 Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients Ogura, Hiromu Hatip-Al-Khatib, Izzettin Suenaga, Midori Hatip, Funda Bolukbasi Mishima, Takayasu Fujioka, Shinsuke Ouma, Shinji Matsunaga, Yoichi Tsuboi, Yoshio eNeurologicalSci Original Article BACKGROUND AND PURPOSE: There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to differentiate between healthy subjects (HS), multiple system atrophy (MSA) and Parkinson's disease (PD) patients of both genders. METHODS: A total of 107 subjects were included in this study, divided into three groups: 1- HS (n = 61), 2- MSA patients (n = 19), and 3- PD patients (n = 27). The patients were assessed using UMSARS II, UPDRS III, H&Y, MMSE and MoCA rating scales. The levels of 25(OH)D and 1,25(OH) 2 D in serum were determined using the radioimmunoassay technique. RESULTS: The levels of 25(OH)D and 1,25(OH) 2 D in HS were 26.85 +/− 7.62 ng/mL and 53.63 +/− 13.66 pg/mL respectively. 25(OH)D levels were lower in both MSA and PD by 61% and 50%, respectively (P = 0.0001 vs. HS). 1,25(OH) 2 D levels were lower in MSA by 29%(P = 0.001 vs HS). There was a correlation between 25(OH)D and 1,25(OH) 2 D in MSA and PD, but not in HS. 1,25(OH) 2 D regressed with MMSE (β = 0.476, P = 0.04, R 2 = 0.226) in MSA, and with UPDRS III (β = −0.432, P = 0.024, R 2 = 0.187) and MoCA (β = 0.582, P = 0.005,R 2 = 0.279) in PD. 25(OH)D displayed considerable differentiative strength between HS and MSA (Wald = 17.123, OR = 0.586, P = 0.0001; AUC = 0.982, sensitivity and Youden index = 0.882, P = 0.0001) and PD (Wald = 18.552, OR = 0.700, P = 0.0001; AUC = 0.943, sensitivity = 0.889, YI = 0.791, P = 0.0001). 1,25(OH) 2 D distinguished MSA from PD (Wald 16.178, OR = 1.117, P = 0.0001; AUC = 0.868, sensitivity = 0.926, Youden index =0.632, P = 0.0001). H&Y exhibited the highest sensitivity, AUC, and significant distinguishing power between MSA and PD. CONCLUSIONS: Serum 25(OH)D and 1,25(OH) 2 D could be useful biomarkers for MSA and PD. 25(OH)D and H&Y provided the highest sensitivity and group classification characteristics. Elsevier 2021-09-23 /pmc/articles/PMC8477135/ /pubmed/34611554 http://dx.doi.org/10.1016/j.ensci.2021.100369 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Ogura, Hiromu Hatip-Al-Khatib, Izzettin Suenaga, Midori Hatip, Funda Bolukbasi Mishima, Takayasu Fujioka, Shinsuke Ouma, Shinji Matsunaga, Yoichi Tsuboi, Yoshio Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients |
title | Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients |
title_full | Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients |
title_fullStr | Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients |
title_full_unstemmed | Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients |
title_short | Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients |
title_sort | circulatory 25(oh)d and 1,25(oh)(2)d as differential biomarkers between multiple system atrophy and parkinson's disease patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477135/ https://www.ncbi.nlm.nih.gov/pubmed/34611554 http://dx.doi.org/10.1016/j.ensci.2021.100369 |
work_keys_str_mv | AT ogurahiromu circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT hatipalkhatibizzettin circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT suenagamidori circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT hatipfundabolukbasi circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT mishimatakayasu circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT fujiokashinsuke circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT oumashinji circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT matsunagayoichi circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT tsuboiyoshio circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients |